RecruitingNCT07621653

Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea

Sponsor

Sanofi

Enrollment

706 participants

Start Date

Jul 1, 2026

Study Type

OBSERVATIONAL

Conditions

Healthy Volunteers Meningococcal Immunization

Summary

This surveillance is to investigate the safety profile of MenQuadfi®, when administered to participants aged 6 weeks to 55 years under the real-world clinical practice settings as per approved indications, including the Adverse Drug Reactions (ADRs)\*. \*It includes ADRs that were not fully recognized in clinical practice, or unexpected ADRs which refer to those not listed in the approved drug labeling.

Eligibility

Min Age: 6 WeeksMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine for people with healthy volunteers and meningococcal immunization. The study is currently recruiting participants at 9 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALMeningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine

This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.

Locations(9)

Investigational Site Number: 410009

Busan, South Korea

Investigational Site Number: 410011

Daegu, South Korea

Investigational Site Number: 410003

Goyang, South Korea

Investigational Site Number: 410008

Gwangju, South Korea

Investigational Site Number: 410010

Hanam, South Korea

Investigational Site Number: 410006

Iksan, South Korea

Investigational Site Number: 410005

Seongnam, South Korea

Investigational Site Number: 410004

Seoul, South Korea

Investigational Site Number: 410007

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07621653

Related Trials

PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects

NCT062994101 location

Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection

NCT077066861 location

Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)

NCT023390121 location

Cybersickness Prevention and Mitigation in Virtual Reality for Healthy Volunteers

NCT065527542 locations

Effects of Daily Footwear Use on Lower Extremity Health and Movement in Healthy Adults

NCT07735949